ERBB2 and breast cancer: Tamoxifen plus fulvestrant for ER-positive BCs and trastuzumab for HER2-positive BC cases is noteworthy as first-line therapy.17 The crucial role of ‘HER2 oncogenic addiction’ in cancer cells underscores the treatment’s efficacy, where downstream signaling through HER2 drives the BC cell proliferation and growth.